Emergency physicians at Penn Presbyterian ED are leading a NIDA funded national study, ED-INNOVATION, to address the optimal formulation of buprenorphine for initiation of MOUD. CAM2038 is a slow release injection of buprenorphine that lasts for 7 days. The study team, led by Dr. Jeanmarie Perrone and including colleagues Dr. David Jang, Dr. Anish Agarwal, Dr. Zachary Meisel and Dr. Sean Foster will assess whether the injection can be a more successful bridge than usual care with sublingual buprenorphine to follow up treatment at 7 days .
If you are struggling with cocaine, and you take prescription Suboxone, a new clinical research study is available for you.
The purpose of this research study is to see whether taking the medication Cariprazine affects drug use in people with opioid and cocaine use disorder. Another purpose of this study is to understand whether certain mental processes (inhibition, memory, decision-making, reward, pain sensitivity, etc.) predict drug use, and whether treatment with Cariprazine impacts these processes.
Participants will be randomly assigned to receive Cariprazine or a placebo for 8 weeks while coming into our offices for twice weekly visits to monitor drug use, receive medication, and respond to research surveys. We will also measure performance on various behavioral and computerized tasks that measure these mental processes. During some tasks, we will monitor your brain activity using a noninvasive neuroimaging technique called functional near-infrared spectroscopy (fNIRS). There is also an option fMRI for those who qualify.
Lead investigators: Kyle Kampman, MD, and Anna Rose Childress, PhD
For more information please CALL: 215-746-3708 or TEXT: “CAR” to 844-917-4646
If you are struggling with opioid use, mental illness, and take prescription Suboxone, a new clinical research study is available for you.
The purpose of this research study is to see whether taking the medication, Olanzapine, affects drug use in people with opioid use and mental illness. Another purpose of the study is to understand whether sleep is affected by Olanzapine.
Participants will receive Olanzapine for 9 weeks while coming into our center for twice weekly visits to monitor drug use, receive medication, and respond to research surveys.
For more information or to refer a patient, please CALL Dyonna at 215-746-2767 or Megan at 215-746-7712.